2020
Lysis of cold‐storage‐induced microvascular obstructions for ex vivo revitalization of marginal human kidneys
DiRito JR, Hosgood SA, Reschke M, Albert C, Bracaglia LG, Ferdinand JR, Stewart BJ, Edwards CM, Vaish AG, Thiru S, Mulligan DC, Haakinson DJ, Clatworthy MR, Saltzman WM, Pober JS, Nicholson ML, Tietjen GT. Lysis of cold‐storage‐induced microvascular obstructions for ex vivo revitalization of marginal human kidneys. American Journal Of Transplantation 2020, 21: 161-173. PMID: 32627324, PMCID: PMC7775334, DOI: 10.1111/ajt.16148.Peer-Reviewed Original ResearchConceptsNormothermic machine perfusionHuman kidneyMicrovascular obstructionMarginal organsHigh-risk donorsSevere organ shortageLikelihood of complicationsMicrovascular blood flowAccumulation of fibrinogenCold storage injuryTissue plasminogen activatorImmediate translational potentialMicrovascular pluggingRenal functionRenal injuryMachine perfusionTubular epitheliumBlood flowIntravascular releaseOrgan shortagePhysiologic impactKidneyTranslational potentialPlasminogen activatorVivo assessment
2016
Eculizumab Therapy for Chronic Antibody‐Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial
Kulkarni S, Kirkiles‐Smith N, Deng YH, Formica RN, Moeckel G, Broecker V, Bow L, Tomlin R, Pober JS. Eculizumab Therapy for Chronic Antibody‐Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. American Journal Of Transplantation 2016, 17: 682-691. PMID: 27501352, DOI: 10.1111/ajt.14001.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, HumanizedChronic DiseaseComplement C5Complement Inactivating AgentsEarly Intervention, EducationalFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionGraft SurvivalHumansIsoantibodiesKidney Failure, ChronicKidney Function TestsKidney TransplantationLiving DonorsMaleMiddle AgedPilot ProjectsPrognosisRisk FactorsTissue DonorsTransplant RecipientsYoung AdultConceptsDe novo donor-specific antibodiesComplement inhibitionTreatment groupsNovo donor-specific antibodiesAntibody-Mediated InjuryC1q-positive patientsDonor-specific antibodiesKidney transplant recipientsPrimary end pointEndothelial cell injuryMo of observationEculizumab therapyEculizumab treatmentHumoral injuryTransplant recipientsKidney transplantRenal functionKidney functionChronic settingEGFR trajectoriesTreatment periodCell injuryPatientsEnd pointPercentage change